Analyzing Eosinophil Characteristics in COPD Patients
Pilot Study for Evaluation of Eosinophils Phenotype and Activation Status in COPD Patients
IRCCS San Raffaele Roma · NCT04494308
This study is testing how certain immune cells called eosinophils behave in people with COPD to see if their characteristics can help understand the disease better and improve treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Roma (other) |
| Locations | 1 site (Roma, RM) |
| Trial ID | NCT04494308 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the immunophenotype of circulating eosinophils in patients with chronic obstructive pulmonary disease (COPD) by analyzing blood samples from both stable and exacerbated patients. The study will utilize multicolor flow cytometry to assess various membrane molecules and intracellular cytokines associated with eosinophil activation and inflammation. By correlating these findings with the clinical status of the patients, the researchers hope to uncover the role of eosinophils in COPD and their potential impact on disease progression and treatment response.
Who should consider this trial
Good fit: Ideal candidates include COPD patients with a percentage of eosinophils greater than 0%, either experiencing an exacerbation or stable condition.
Not a fit: Patients with a percentage of eosinophils equal to 0% or those with a history of allergic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of COPD exacerbations through eosinophil profiling.
How similar studies have performed: While studies have explored eosinophil roles in other conditions, this specific approach in COPD is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * COPD * percentage of eosinophils \>0% * episode of exacerbation in the previous 10 days (for exacerbated cohort) * no exacerbation in the previous 3 months (for stable cohort) Exclusion Criteria: * percentage of eosinophils =0% * history of allergic diseases * patients that are currently enrolled in other clinical trials involving new drugs or treatments
Where this trial is running
Roma, RM
- IRCCS San Raffaele Pisana — Roma, RM, Italy (RECRUITING)
Study contacts
- Principal investigator: Laura Vitiello, PhD — IRCCS San Raffaele Pisana, Roma
- Study coordinator: Vittorio Cardaci, MD
- Email: vittorio.cardaci@sanraffaele.it
- Phone: +39 0666052336
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COPD, COPD Exacerbation, eosinophils, immunophenotype, inflammation